Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program
Compugen Ltd. has received a 'Buy' rating due to promising early data on its gastric cancer treatment program, Rilvegostomig. The company is expected to see significant advancements in its clinical programs and upcoming catalysts in the oncology sector. This positive outlook is supported by the ongoing developments in their research and potential market impact.
- ▪Compugen Ltd. is currently rated as a 'Buy' by analysts.
- ▪The company's Rilvegostomig program shows promising early data for gastric cancer treatment.
- ▪Upcoming catalysts in oncology are expected to drive the company's growth.
Opening excerpt (first ~120 words) tap to expand
{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https://seekingalpha.com/"},{"@type":"ListItem","position":2,"name":"Earnings Analysis","item":"https://seekingalpha.com/earnings/earnings-analysis"},{"@type":"ListItem","position":3,"name":"Healthcare ","item":"https://seekingalpha.com/stock-ideas/healthcare"}]}{"@context":"https://schema.org","@type":"NewsArticle","mainEntityOfPage":{"@type":"WebPage","@id":"https://seekingalpha.com/article/4906399-compugen-buy-as-early-gastric-cancer-data-reinforces-rilvegostomig-program"},"author":{"@type":"Person","name":"Terry…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Seeking Alpha.
Discussion
0 commentsMore from Seeking Alpha
